Advertisement
UK markets closed

  • FTSE 100

    8,237.72
    -34.74 (-0.42%)
     

  • FTSE 250

    20,442.35
    -56.37 (-0.27%)
     

  • AIM

    772.57
    +0.19 (+0.02%)
     

  • GBP/EUR

    1.1829
    +0.0007 (+0.06%)
     

  • GBP/USD

    1.2651
    -0.0009 (-0.07%)
     

  • Bitcoin GBP

    50,811.34
    -585.92 (-1.14%)
     

  • CMC Crypto 200

    1,328.68
    -31.65 (-2.33%)
     

  • S&P 500

    5,464.62
    -8.55 (-0.16%)
     

  • DOW

    39,150.33
    +15.57 (+0.04%)
     

  • CRUDE OIL

    80.64
    -0.65 (-0.80%)
     

  • GOLD FUTURES

    2,334.80
    -34.20 (-1.44%)
     

  • NIKKEI 225

    38,596.47
    -36.55 (-0.09%)
     

  • HANG SENG

    18,028.52
    -306.80 (-1.67%)
     

  • DAX

    18,163.52
    -90.66 (-0.50%)
     

  • CAC 40

    7,628.57
    -42.77 (-0.56%)
     
Property:

Homes with impressive sports facilities

Properties with tennis and basketball courts to pools and even a football pitch at the doorstep

TG Therapeutics to Participate in the Jefferies Global Healthcare Conference

TG Therapeutics, Inc.
·1-min read
TG Therapeutics, Inc.
TG Therapeutics, Inc.

Fireside chat scheduled for Wednesday, June 5, 2024, at 1:30 PM ET

NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Jefferies Global Healthcare Conference, being held at the Marriott Marquis, in New York City on June 5-6, 2024. The fireside chat is scheduled to take place on Wednesday, June 5, 2024, at 1:30 PM ET.

A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events.

ADVERTISEMENT

ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received U.S. Food and Drug Administration (FDA) approval for BRIUMVI® (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features in Europe and the United Kingdom, respectively. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.

BRIUMVI® is a registered trademark of TG Therapeutics, Inc.

CONTACT:

Investor Relations
Email: ir@tgtxinc.com 
Telephone: 1.877.575.TGTX (8489), Option 4

Media Relations:
Email: media@tgtxinc.com 
Telephone: 1.877.575.TGTX (8489), Option 6